home.html home.html
    • corporation_overview.html corporation_overview.html
    • press_releases.html press_releases.html
    • investors_overview.html investors_overview.html
    • los_angeles_california.html los_angeles_california.html
    • contact_us.html contact_us.html
    • chaperone_overview.html chaperone_overview.html
    • technologies_overview.html technologies_overview.html
    • therapeutics_overview.html therapeutics_overview.html

    • CytRx Corporation (NASDAQ: CYTR), is a biopharmaceutical company engaged in the development of high-value therapeutics based on its small molecule chaperone amplification technology.

     

    About CytRx Corp >

    News & Events >

    Investor Relations >

    Careers >

    Contact Us >

    CytRx is developing products based on small molecule chaperone amplification technology in a variety of therapeutic indications including ALS, stroke recovery and diabetic wound healing.  In addition, CytRx owns approximately 49% of RXi Pharmaceuticals Corporation (NASD: RXII), a discovery-stage biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of human diseases

     

    About Platform Technologies >

    Chaperone Amplification >

    RXi Pharmaceuticals Corporation >
    4/23/2008 - CytRx Announces Discovery of Novel Compounds that Amplify Chaperone Response to Cell Stress news_details_1.html  More »
    4/2/2008 - CytRx Reports 2007 Financial Results news_details_3.html  More »
    3/26/2008 - CytRx to Present Stroke Recovery Data at the Sixth International Workshop on The Molecular Biology of Stress Responses news_details_4.html  More »
    3/24/2008 - CytRx Submits Response to FDA Related to Clinical Program with Arimoclomol in ALS news_details_2.html  More »

    See more press releases >

    2/20/2008 - CytRx to present at Roth Capital Partners 20th Annual OC Growth Stock Conference  5:00p.m. PT

     

    2/11/2008 - CytRx to Present at BIO CEO Investor Conference 1:15p.m. ET

     

    1/22/2008 - CytRx Corporation Business Update 10:00 a.m. ET

     

     

    CytRx is supported by strong financial resources and world class collaborators to build a pipeline of "molecular chaperone inductions" product candidates.

     

    Investor Relations >

    Corporate Governance >

    SEC Filings >

    Information Request >